http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021
-
Sutro Biopharma to Participate in Two Upcoming Investor Conferences
-
Sutro Biopharma Inc. (STRO) Appoints Heidi Hunter to its Board
-
Sutro Biopharma Announces Appointment of Heidi Hunter to Board of Directors
-
Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones
-
Sutro Biopharma to Participate in Three Upcoming Investor Conferences
-
Sutro Biopharma Inc. (STRO) Announces Collaboration with BioNova Pharmaceuticals for STRO-001 in Greater China
-
Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China
-
Sutro Biopharma (STRO) Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck
-
Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck
-
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sutro Biopharma Announces Expansion of Leadership Team
-
Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
-
Sutro Biopharma (STRO) Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
-
Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
-
Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones
-
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
-
Sutro Biopharma to Participate in the 12th Annual Wedbush PacGrow Healthcare Virtual Conference
-
Sutro Biopharma to Participate in Two Virtual Investor Conferences in June
-
Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany
-
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021
-
Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences
-
Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones
-
Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer
-
Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
-
Sutro Biopharma to Present at Two Upcoming Investor Conferences
-
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
-
Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones
-
Sutro Biopharma Inc. (STRO) Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at ASH
-
Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
-
Sutro Biopharma Inc. (STRO) Reports Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
-
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
-
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
-
Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
-
Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
-
Sutro Biopharma to Participate in Four Upcoming Investor Conferences
-
Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments
-
Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC
-
Sutro Biopharma Inc. (STRO) Highlights Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer
-
Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting
-
Sutro Biopharma to Present at Two Upcoming Investor Conferences
-
Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting
-
Sutro Biopharma Inc. (STRO) Earns Clinical Supply Milestone Payment from Merck KGaA for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
-
Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
-
Sutro Biopharma Announces Two Executive Promotions to Vice President of Quality and Vice President of Manufacturing
-
Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
-
Sutro Biopharma Reports Second Quarter 2020 Financial Results and Provides Business Highlights and Developments
-
Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor
-
Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020
-
Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
